Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas

John P. Crown, Subhash Gulati, David J. Straus, Jonathan Kolitz, Robert Heelan, James O'Brien, Burton J. Lee, Carol Portlock, Joseph Bertino

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

As part of a program to develop less leukemogenic chemotherapy regimens for the treatment of favorable prognosis Hodgkin's disease, a phase I-II trial of mitoxantrone, etoposide, mitoguazone, and vinblastine was used to treat patients with relapsed and refractory malignant lymphoma and Hodgkin's disease. An over-all partial response rate of 41% was observed. Although useful responses were seen, the absence of complete remissions is disappointing.

Original languageEnglish (US)
Pages (from-to)185-186
Number of pages2
JournalInvestigational New Drugs
Volume9
Issue number2
DOIs
StatePublished - May 1 1991

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Keywords

  • etoposide
  • mitoguazone
  • mitoxantrone
  • relapsed/refractory lymphomas
  • vinblastine

Fingerprint Dive into the research topics of 'Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV<sup>2</sup>) in relapsed and refractory lymphomas'. Together they form a unique fingerprint.

Cite this